- Home
- CARM vs GANX Comparison
CARM vs GANX Comparison
Compare CARM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- GANX
- Stock Information
- Founded
- CARM 2016
- GANX 2017
- Country
- CARM United States
- GANX United States
- Employees
- CARM N/A
- GANX N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- GANX Health Care
- Exchange
- CARM Nasdaq
- GANX Nasdaq
- Market Cap
- CARM 35.5M
- GANX 41.9M
- IPO Year
- CARM N/A
- GANX 2021
- Fundamental
- Price
- CARM $0.47
- GANX $1.58
- Analyst Decision
- CARM Hold
- GANX Strong Buy
- Analyst Count
- CARM 5
- GANX 5
- Target Price
- CARM $4.57
- GANX $7.60
- AVG Volume (30 Days)
- CARM 329.1K
- GANX 203.8K
- Earning Date
- CARM 11-07-2024
- GANX 11-14-2024
- Dividend Yield
- CARM N/A
- GANX N/A
- EPS Growth
- CARM N/A
- GANX N/A
- EPS
- CARM N/A
- GANX N/A
- Revenue
- CARM $20,268,000.00
- GANX N/A
- Revenue This Year
- CARM $46.34
- GANX N/A
- Revenue Next Year
- CARM N/A
- GANX N/A
- P/E Ratio
- CARM N/A
- GANX N/A
- Revenue Growth
- CARM 41.13
- GANX N/A
- 52 Week Low
- CARM $0.38
- GANX $0.89
- 52 Week High
- CARM $3.16
- GANX $5.33
- Technical
- Relative Strength Index (RSI)
- CARM 21.83
- GANX 42.64
- Support Level
- CARM $0.38
- GANX $1.59
- Resistance Level
- CARM $0.82
- GANX $1.70
- Average True Range (ATR)
- CARM 0.06
- GANX 0.15
- MACD
- CARM -0.03
- GANX 0.00
- Stochastic Oscillator
- CARM 18.22
- GANX 19.74
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.